Syngene International Ltd, a wholly owned subsidiary of Biocon Ltd, and Baxter International, a global pharmaceutical company, have collaborated to establish the Baxter Global Research Center at Syngene in Bangalore.

The Baxter Global Research Center (BGRC) at Syngene is part of Baxter’s global strategy of building R&D collaborations with strategic partners. This collaboration will support Baxter in the research and development of medical products and devices to serve patients both in India and around the world.

A team of over 100 multidisciplinary Syngene scientists will be based at this dedicated centre of excellence at Syngene in Biocon Park, Bangalore.

Kiran Mazumdar Shaw, Chairperson, Biocon, said: “We share a common vision with Baxter, focused on developing pharmaceutical products that advance patient care worldwide, and this new research centre will be a significant step towards enabling that objective.”

The Syngene team, working closely with Baxter scientists, will engage in a wide range of R&D activities centered on product and analytical development and pre-clinical evaluation in parenteral nutrition and renal therapy.

Jean-Luc Butel, Corporate Vice-President & President-International, Baxter, said: “Baxter is pleased to be part of the opening of this Syngene facility dedicated to providing Baxter with technical and scientific capabilities that will augment our own internal resources. Baxter is committed to helping save and sustain patients’ lives worldwide, and innovation is the driver of success in this area.”

Commenting on the collaboration, Peter Bains, Director, Syngene International Ltd, said: “The scale and scope of activities signal the strategic nature of the collaboration and also reflect Syngene’s capabilities to offer broad-based complimentary integrated development services.”

Related Topics
comment COMMENT NOW